
Boston Scientific Corporation: shareholders and insiders
Price
$43.03
November 17, 2026Market cap $63.9B
What Ploutos Investor adds for Boston Scientific
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 18, 2025 to Nov 6, 2026, from their own Form 4 filings.
Bought on the market
$10M
5 people
Sold on the market
$17M
2 people
From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $10M by 5 people·sold $15M by 1 person
- 2025: no buys, sold $1.8M by 1 person
- 2026: bought $10M by 5 people, sold $15M by 1 person
- Nov 4, 2026Michael F MahoneyChairman, President & CEOKind
- Nov 4, 2026Michael F MahoneyChairman, President & CEOKind
- Nov 1, 2026Miriam O'SullivanSVP, Chief HR OfficerKind
- Nov 1, 2026Miriam O'SullivanSVP, Chief HR OfficerKind
- Sep 2, 2026Padraig Andrew O'ConnorEVP, Global OperationsKind
- Sep 2, 2026Padraig Andrew O'ConnorEVP, Global OperationsKind
- Aug 25, 2026Susan E MoranoDirectorKind
- Aug 11, 2026Emily WoodworthSVP, Global Controller and CAOKind
- Aug 10, 2026Jonathan MonsonEVP and CFOKind
- Aug 5, 2026David C HabigerDirectorKind
- Aug 4, 2026David C HabigerDirectorKind
- Aug 3, 2026David C HabigerDirectorKind
- Aug 3, 2026Michael F MahoneyChairman, President & CEOKind
- Aug 3, 2026Michael F MahoneyChairman, President & CEOKind
- Jul 31, 2026Edward J LudwigDirectorKind
- Jul 31, 2026Joseph Michael FitzgeraldEVP & Group Pres, CardiologyKind
- Jul 1, 2026Jonathan MonsonEVP and CFOKind
- Jul 1, 2026Jonathan MonsonEVP and CFOKind
- May 28, 2026Michael F MahoneyChairman, President & CEOKind
- May 20, 2026David C HabigerKind
- May 20, 2026Edward J LudwigKind
- May 20, 2026Cheryl PegusKind
- May 19, 2026David C HabigerKind
- Feb 2, 2026Michael F MahoneyChairman, President & CEOKind10b5-1
- Feb 2, 2026Michael F MahoneyChairman, President & CEOKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | Michael F MahoneyChairman, President & CEO | 150.0K | – | – | Form 4 | |
| Nov 4, 2026 | Michael F MahoneyChairman, President & CEO | 102.2K | – | – | Form 4 | |
| Nov 1, 2026 | Miriam O'SullivanSVP, Chief HR Officer | 3,871 | – | – | Form 4 | |
| Nov 1, 2026 | Miriam O'SullivanSVP, Chief HR Officer | 1,872 | $41.98 | $78.6K | Form 4 | |
| Sep 2, 2026 | Padraig Andrew O'ConnorEVP, Global Operations | 1,171 | – | – | Form 4 | |
| Sep 2, 2026 | Padraig Andrew O'ConnorEVP, Global Operations | 567 | $48.37 | $27.4K | Form 4 | |
| Aug 25, 2026 | Susan E MoranoDirector | 2,040 | $49.22 | $100.4K | Form 4 | |
| Aug 11, 2026 | Emily WoodworthSVP, Global Controller and CAO | 2,930 | $51.19 | $150.0K | Form 4 | |
| Aug 10, 2026 | Jonathan MonsonEVP and CFO | 9,908 | $50.46 | $500.0K | Form 4 | |
| Aug 5, 2026 | David C HabigerDirector | 2,100 | $47.59 | $99.9K | Form 4 | |
| Aug 4, 2026 | David C HabigerDirector | 140 | $48.59 | $6.8K | Form 4 | |
| Aug 3, 2026 | David C HabigerDirector | 1,042 | $48.07 | $50.1K | Form 4 | |
| Aug 3, 2026 | Michael F MahoneyChairman, President & CEO | 186.2K | $48.33 | $9.0M | Form 4 | |
| Aug 3, 2026 | Michael F MahoneyChairman, President & CEO | 22.1K | $48.43 | $1.1M | Form 4 | |
| Jul 31, 2026 | Edward J LudwigDirector | 5,000 | $45.48 | $227.4K | Form 4 | |
| Jul 31, 2026 | Joseph Michael FitzgeraldEVP & Group Pres, Cardiology | 64.2K | $46.73 | $3.0M | Form 4 | |
| Jul 1, 2026 | Jonathan MonsonEVP and CFO | 2,087 | – | – | Form 4 | |
| Jul 1, 2026 | Jonathan MonsonEVP and CFO | 1,010 | $43.06 | $43.5K | Form 4 | |
| May 28, 2026 | Michael F MahoneyChairman, President & CEO | 386.8K | – | – | Form 4 | |
| May 20, 2026 | David C Habiger | 2,250 | $55.92 | $125.8K | Form 4 | |
| May 20, 2026 | Edward J Ludwig | 3,580 | $56.68 | $202.9K | Form 4 | |
| May 20, 2026 | Cheryl Pegus | 1,770 | $56.49 | $100.0K | Form 4 | |
| May 19, 2026 | David C Habiger | 2,200 | $56.95 | $125.3K | Form 4 | |
| Feb 2, 2026 | Michael F MahoneyChairman, President & CEO | 10b5-1 | 1,200 | $94.06 | $112.9K | Form 4 |
| Feb 2, 2026 | Michael F MahoneyChairman, President & CEO | 10b5-1 | 159.7K | $93.49 | $15M | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 1, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by BSX's officers and directors from 2006 up to November 17, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- D.E. ShawIn the quarter-17%
- AQR CapitalIn the quarter+151%
- Citadel Advisors (Griffin)In the quarter+57%
- Renaissance TechnologiesIn the quarter-27%
- Bridgewater (Dalio)In the quarter-1.1%
- Glenview CapitalIn the quarter-38%
- Point72 (Cohen)In the quarter
- Millennium Mgmt (Englander)In the quarter-79%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| D.E. Shaw | 21.25M | -17% | $927M | 0.58% |
| AQR Capital | 24.32M | +151% | $1.1B | 0.31% |
| Citadel Advisors (Griffin) | 7.81M | +57% | $341M | 0.19% |
| Renaissance Technologies | 1.77M | -27% | $77M | 0.10% |
| Bridgewater (Dalio) | 437.2K | -1.1% | $19M | 0.08% |
| Glenview Capital | 70.3K | -38% | $3.1M | 0.05% |
| Point72 (Cohen) | – | – | 0.02% | |
| Millennium Mgmt (Englander) | 1.12M | -79% | $27M | 0.02% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 2.74% of its shares outstanding were held short, -1.7% since the report before.
- Shares held short
- 40.71M
- 2.74%
- Since the report before41.41M on Sep 30, 2026
- -1.7%
- 2.6
- 15.74M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 30%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 9.14M
- Nov 15, 2023: Shares held short 11.85M
- Nov 30, 2023: Shares held short 9.24M
- Dec 15, 2023: Shares held short 11.64M
- Dec 29, 2023: Shares held short 9.35M
- Jan 12, 2024: Shares held short 11.43M
- Jan 31, 2024: Shares held short 10.87M
- Feb 15, 2024: Shares held short 11.03M
- Feb 29, 2024: Shares held short 9.44M
- Mar 15, 2024: Shares held short 11.48M
- Mar 28, 2024: Shares held short 12.43M
- Apr 15, 2024: Shares held short 13.16M
- Apr 30, 2024: Shares held short 13.94M
- May 15, 2024: Shares held short 12.33M
- May 31, 2024: Shares held short 13.38M
- Jun 14, 2024: Shares held short 11.54M
- Jun 28, 2024: Shares held short 11.25M
- Jul 15, 2024: Shares held short 11.53M
- Jul 31, 2024: Shares held short 10.80M
- Aug 15, 2024: Shares held short 10.74M
- Aug 30, 2024: Shares held short 11.02M
- Sep 13, 2024: Shares held short 12.20M
- Sep 30, 2024: Shares held short 10.92M
- Oct 15, 2024: Shares held short 11.31M
- Oct 31, 2024: Shares held short 12.91M
- Nov 15, 2024: Shares held short 11.02M
- Nov 29, 2024: Shares held short 12.25M
- Dec 13, 2024: Shares held short 12.33M
- Dec 31, 2024: Shares held short 14.52M
- Jan 15, 2025: Shares held short 14.40M
- Jan 31, 2025: Shares held short 10.45M
- Feb 14, 2025: Shares held short 11.46M
- Feb 28, 2025: Shares held short 12.87M
- Mar 14, 2025: Shares held short 12.62M
- Mar 31, 2025: Shares held short 13.10M
- Apr 15, 2025: Shares held short 14.49M
- Apr 30, 2025: Shares held short 15.71M
- May 15, 2025: Shares held short 16.75M
- May 30, 2025: Shares held short 17.02M
- Jun 13, 2025: Shares held short 17.49M
- Jun 30, 2025: Shares held short 19.05M
- Jul 15, 2025: Shares held short 19.57M
- Jul 31, 2025: Shares held short 16.27M
- Aug 15, 2025: Shares held short 18.60M
- Aug 29, 2025: Shares held short 18.99M
- Sep 15, 2025: Shares held short 19.02M
- Sep 30, 2025: Shares held short 19.40M
- Oct 15, 2025: Shares held short 19.63M
- Oct 31, 2025: Shares held short 19.45M
- Nov 14, 2025: Shares held short 21.08M
- Nov 28, 2025: Shares held short 18.73M
- Dec 15, 2025: Shares held short 19.14M
- Dec 31, 2025: Shares held short 20.01M
- Jan 15, 2026: Shares held short 23.42M
- Jan 30, 2026: Shares held short 28.28M
- Feb 13, 2026: Shares held short 26.64M
- Feb 27, 2026: Shares held short 26.26M
- Mar 13, 2026: Shares held short 25.44M
- Mar 31, 2026: Shares held short 23.53M
- Apr 15, 2026: Shares held short 25.61M
- Apr 30, 2026: Shares held short 28.64M
- May 15, 2026: Shares held short 31.42M
- May 29, 2026: Shares held short 57.49M
- Jun 15, 2026: Shares held short 29.75M
- Jun 30, 2026: Shares held short 27.94M
- Jul 15, 2026: Shares held short 28.28M
- Jul 31, 2026: Shares held short 22.28M
- Aug 14, 2026: Shares held short 27.62M
- Aug 31, 2026: Shares held short 48.17M
- Sep 15, 2026: Shares held short 46.50M
- Sep 30, 2026: Shares held short 41.41M
- Oct 15, 2026: Shares held short 40.71M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading32.9% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 32.9% of the shares in the reported trades were short sales, against 39.1% in the 14 before.
- Last 14 sessionsOct 29, 2026 – Nov 17, 2026
- 32.9%
- The 14 beforeOct 9, 2026 – Oct 28, 2026
- 39.1%
- Change
- -6.2 pts
- Short sales a dayon average, of 7.40M shares
- 2.44M
- More than atof 3,666 US-listed companies, same days
- 7%
- Median of alleight in ten from 34.6% to 63.7%
- 50.3%
- Short sales
- Oct 9, 2026: Short sales 30.5%
- Oct 12, 2026: Short sales 41.2%
- Oct 13, 2026: Short sales 41.7%
- Oct 14, 2026: Short sales 44.5%
- Oct 15, 2026: Short sales 34.1%
- Oct 16, 2026: Short sales 41.4%
- Oct 19, 2026: Short sales 35.4%
- Oct 20, 2026: Short sales 41.9%
- Oct 21, 2026: Short sales 51.2%
- Oct 22, 2026: Short sales 53.8%
- Oct 23, 2026: Short sales 52.6%
- Oct 26, 2026: Short sales 27.5%
- Oct 27, 2026: Short sales 22.7%
- Oct 28, 2026: Short sales 37.8%
- Oct 29, 2026: Short sales 23.5%
- Oct 30, 2026: Short sales 27%
- Nov 2, 2026: Short sales 36.7%
- Nov 3, 2026: Short sales 41.6%
- Nov 4, 2026: Short sales 37.1%
- Nov 5, 2026: Short sales 36.6%
- Nov 6, 2026: Short sales 39.2%
- Nov 9, 2026: Short sales 44.8%
- Nov 10, 2026: Short sales 34.6%
- Nov 11, 2026: Short sales 29.2%
- Nov 12, 2026: Short sales 31.2%
- Nov 13, 2026: Short sales 25%
- Nov 16, 2026: Short sales 25.3%
- Nov 17, 2026: Short sales 24.5%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Michael F MahoneyChairman, President & CEODirectly1.86M
- Joseph Michael FitzgeraldEVP & Group Pres, CardiologyDirectly283.3K
- Daniel J. BrennanEVP and CFODirectly225.8K
- Jonathan MonsonEVP and CFODirectly49.0K
- Eric Francis Yves ThepautEVP & Pres, Eur, Mid-East, AfrDirectly31.4K
- Vance R BrownSVP, GC and Corp. SecretaryDirectly31.4K
- Edward J LudwigDirectorDirectly30.4K
- Wendy CarruthersEVP, Human ResourcesDirectly29.3K
- Jeffrey B. MirvissEVP&Pres, Periph InterventDirectly25.8K
- Ellen M ZaneDirectorDirectly24.1K
- Arthur C ButcherEVP& Grp Pres, MedSurg & APACDirectly23.6K
- Miriam O'SullivanSVP, Chief HR OfficerDirectly21.3K
- John Bradley SorensonEVP, Global OperationsDirectly18.7K
- David C HabigerDirectorDirectly17.2K
- Susan E MoranoDirectorDirectly13.8K
- Padraig Andrew O'ConnorEVP, Global OperationsDirectly7,892
- Emily WoodworthSVP, Global Controller and CAODirectly6,053
- Yoshiaki FujimoriDirectorDirectly2,081
- Cheryl PegusDirectorDirectly1,770
- Charles J DockendorffDirectorDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Michael F MahoneyChairman, President & CEO | 1.86M | – | Nov 4, 2026 | Form 4 |
| Joseph Michael FitzgeraldEVP & Group Pres, Cardiology | 283.3K | – | Jul 31, 2026 | Form 4 |
| Daniel J. BrennanEVP and CFO | 225.8K | – | Feb 19, 2025 | Form 4 |
| Jonathan MonsonEVP and CFO | 49.0K | – | Aug 10, 2026 | Form 4 |
| Eric Francis Yves ThepautEVP & Pres, Eur, Mid-East, Afr | 31.4K | – | May 10, 2024 | Form 4 |
| Vance R BrownSVP, GC and Corp. Secretary | 31.4K | – | May 21, 2025 | Form 4 |
| Edward J LudwigDirector | 30.4K | – | Jul 31, 2026 | Form 4 |
| Wendy CarruthersEVP, Human Resources | 29.3K | – | Dec 2, 2024 | Form 4 |
| Jeffrey B. MirvissEVP&Pres, Periph Intervent | 25.8K | – | Feb 25, 2025 | Form 4 |
| Ellen M ZaneDirector | 24.1K | – | Nov 6, 2025 | Form 4 |
| Arthur C ButcherEVP& Grp Pres, MedSurg & APAC | 23.6K | – | Dec 1, 2025 | Form 4 |
| Miriam O'SullivanSVP, Chief HR Officer | 21.3K | – | Nov 1, 2026 | Form 4 |
| John Bradley SorensonEVP, Global Operations | 18.7K | – | May 5, 2025 | Form 4 |
| David C HabigerDirector | 17.2K | – | Aug 5, 2026 | Form 4 |
| Susan E MoranoDirector | 13.8K | – | Aug 25, 2026 | Form 4 |
| Padraig Andrew O'ConnorEVP, Global Operations | 7,892 | – | Sep 2, 2026 | Form 4 |
| Emily WoodworthSVP, Global Controller and CAO | 6,053 | – | Aug 11, 2026 | Form 4 |
| Yoshiaki FujimoriDirector | 2,081 | – | Jul 29, 2025 | Form 4 |
| Cheryl PegusDirector | 1,770 | – | May 20, 2026 | Form 4 |
| Charles J DockendorffDirector | – | – | May 7, 2024 | Form 4 |
A lower bound: it counts only the 20 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
10b5-1 trading plans
Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.
- Michael F. MahoneyChairman and Chief Executive OfficerWhat happenedAdoptedAug 12, 2026Shares98.8K
- Michael F. MahoneyChairman and Chief Executive OfficerWhat happenedEndedFeb 19, 2026Shares–
- Miriam O’SullivanSenior Vice President and Chief Human Resources OfficerWhat happenedAdoptedNov 13, 2025Shares14.9K
- Michael F. MahoneyChairman and Chief Executive OfficerWhat happenedAdoptedAug 29, 2025Shares–
- Arthur C. ButcherExecutive Vice President and Group President, MedSurg and Asia PacificWhat happenedAdoptedAug 28, 2025Shares–
- Jeffrey B. MirvissSenior Vice President and President, Peripheral InterventionsWhat happenedAdoptedAug 28, 2025Shares–
- Ellen M. Zaneindependent member of our Board of DirectorsWhat happenedAdoptedJul 25, 2025Shares–
- Emily M. WoodworthSenior Vice President, Global Controller and Chief Accounting OfficerWhat happenedAdoptedNov 29, 2024Shares–
- Jeffrey B. MirvissSenior Vice President and President, Peripheral InterventionsWhat happenedAdoptedNov 21, 2024Shares–
- Vance R. BrownSenior Vice President, General Counsel and Corporate SecretaryWhat happenedAdoptedNov 21, 2024Shares19.3K
| Person | What happened | Until | Shares | Filing |
|---|---|---|---|---|
| Michael F. MahoneyChairman and Chief Executive Officer | AdoptedAug 12, 2026 | 200 days | 98.8K | 10-Q |
| Michael F. MahoneyChairman and Chief Executive Officer | EndedFeb 19, 2026 | – | – | 10-Q |
| Miriam O’SullivanSenior Vice President and Chief Human Resources Officer | AdoptedNov 13, 2025 | Dec 31, 2026 | 14.9K | 10-K |
| Michael F. MahoneyChairman and Chief Executive Officer | AdoptedAug 29, 2025 | Apr 17, 2026 | – | 10-Q |
| Arthur C. ButcherExecutive Vice President and Group President, MedSurg and Asia Pacific | AdoptedAug 28, 2025 | Feb 1, 2027 | – | 10-Q |
| Jeffrey B. MirvissSenior Vice President and President, Peripheral Interventions | AdoptedAug 28, 2025 | Feb 27, 2026 | – | 10-Q |
| Ellen M. Zaneindependent member of our Board of Directors | AdoptedJul 25, 2025 | Oct 23, 2026 | – | 10-Q |
| Emily M. WoodworthSenior Vice President, Global Controller and Chief Accounting Officer | AdoptedNov 29, 2024 | Aug 29, 2025 | – | 10-K |
| Jeffrey B. MirvissSenior Vice President and President, Peripheral Interventions | AdoptedNov 21, 2024 | May 21, 2025 | – | 10-K |
| Vance R. BrownSenior Vice President, General Counsel and Corporate Secretary | AdoptedNov 21, 2024 | May 30, 2025 | 19.3K | 10-K |
As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$24M
Actually paid: $33M
$5.8M
Actually paid: $5.9M
$265
Peers: $148
Adjusted Net Sales
$19.9B
From the proxy statement (DEF 14A) of Mar 18, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
The shareholders' vote on pay
The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.
- 2026May 5, 2026For90.8%
- 2024May 6, 2024For92.7%
- 2023May 9, 2023For92.6%
- 2022May 6, 2022For89.7%
- 2021May 11, 2021For92.6%
| Year | For | Votes for | Votes against | Abstentions | Broker non-votes | Filing |
|---|---|---|---|---|---|---|
| 2026May 5, 2026 | 90.8% | 1.10B | 111M | 2.86M | 81.27M | 8-K |
| 2024May 6, 2024 | 92.7% | 1.16B | 90.95M | 3.23M | 73.10M | 8-K |
| 2023May 9, 2023 | 92.6% | 1.13B | 90.35M | 872.6K | 40.48M | 8-K |
| 2022May 6, 2022 | 89.7% | 1.09B | 124M | 2.40M | 33.42M | 8-K |
| 2021May 11, 2021 | 92.6% | 1.11B | 89.15M | 884.9K | 35.94M | 8-K |
From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHIiShares U.S. Medical Devices ETFWeight in the fund3.99%
- IYHiShares U.S. Healthcare ETFWeight in the fund1.14%
- XLVState Street(R) Health Care Select Sector SPDR(R) ETFWeight in the fund1.10%
- BLCRiShares Large Cap Core Active ETFWeight in the fund1.02%
- VHTVanguard Health Care Index FundWeight in the fund0.99%
- IXJiShares Global Healthcare ETFWeight in the fund0.82%
- MGKVanguard Mega Cap Growth Index FundWeight in the fund0.28%
- IWXiShares Russell Top 200 Value ETFWeight in the fund0.25%
- USMViShares MSCI USA Min Vol Factor ETFWeight in the fund0.24%
- SCHVSchwab U.S. Large-Cap Value ETFWeight in the fund0.23%
54 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 1,718
- Q4 2025: Managers 1,792
- Q1 2026: Managers 1,683
- Q2 2026: Managers 1,474
Institutional investors by quarter
The fund managers holding BSX, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 1,474 managers held 1.34B shares, worth $57.6B. During the quarter 146 opened a position, 355 closed one, 584 added and 608 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter-1.6%
- Vanguard Capital ManagementIn the quarter+0.7%
- State StreetIn the quarter+3.1%
- Primecap ManagementIn the quarter+55%
- FMRIn the quarter-38%
- Geode Capital ManagementIn the quarter+0.5%
- Vanguard Portfolio ManagementIn the quarter
- D.E. ShawIn the quarter+4.7%
- Massachusetts Financial ServicesIn the quarter+126%
- JPMorgan ChaseIn the quarter-28%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 130M | -1.6% | $5.5B |
| Vanguard Capital Management | 97.09M | +0.7% | $4.1B |
| State Street | 70.11M | +3.1% | $3.0B |
| Primecap Management | 50.52M | +55% | $2.2B |
| FMR | 45.70M | -38% | $2.0B |
| Geode Capital Management | 33.44M | +0.5% | $1.4B |
| Vanguard Portfolio Management | 29.79M | $1.3B | |
| D.E. Shaw | 25.46M | +4.7% | $1.1B |
| Massachusetts Financial Services | 24.86M | +126% | $1.5B |
| JPMorgan Chase | 23.91M | -28% | $1.0B |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do Boston Scientific's filings show?
Who buys and sells is one part of Boston Scientific's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have BSX's insiders bought or sold?
From Jun 1, 2026 to Nov 6, 2026 Boston Scientific's insiders bought $9.5M and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.
Which well-known managers hold BSX?
8 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $1.1B.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.